Trifluridine/tipiracil plus ramucirumab in gastric cancer
Lancet Gastroenterol Hepatol
.
2021 Mar;6(3):154-155.
doi: 10.1016/S2468-1253(21)00013-3.
Epub 2021 Jan 26.
Authors
Mojun Zhu
1
,
Mohamad Bassam Sonbol
2
,
Harry H Yoon
3
Affiliations
1
Mayo Clinic, Rochester, MN 55905, USA.
2
Mayo Clinic, Phoenix, AZ, USA.
3
Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
[email protected]
.
PMID:
33508243
PMCID:
PMC8447873
DOI:
10.1016/S2468-1253(21)00013-3
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Pyrrolidines
Ramucirumab
Stomach Neoplasms* / drug therapy
Thymine
Trifluridine*
Substances
Antibodies, Monoclonal, Humanized
Pyrrolidines
tipiracil
Thymine
Trifluridine
Grants and funding
R01 CA248147/CA/NCI NIH HHS/United States